Source comparison
Comparison: Tesamorelin vs Ipamorelin vs Combined Protocol
Tesamorelin (monotherapy) GHRH receptor (pituitary somatotrophs) 2mg daily, single morning dose 15.2% (NEJM trial data) High-amplitude single daily peak FDA-approved for HIV lipodystrophy Gold standard for targeted visceral fat reduction with the strongest cli
This comparison does not assign a generated winner or score.
- Tesamorelin (monotherapy)
- GHRH receptor (pituitary somatotrophs)
- 2mg daily, single morning dose
- 15.2% (NEJM trial data)
- High-amplitude single daily peak
- FDA-approved for HIV lipodystrophy
- Gold standard for targeted visceral fat reduction with the strongest clinical evidence, but limited to single daily GH surge
- Ipamorelin (monotherapy)
- Ghrelin receptor (GHS-R1a)
- 200–300mcg, 2–3× daily
- 8–12% (observational data, not RCT-validated)
- Moderate-amplitude multiple daily peaks
- Investigational, no FDA approval
- Physiologically mimics natural pulsatile GH secretion better than single-dose compounds, but weaker per-dose response and lacks controlled trial data
- Combined Protocol
- Both GHRH and ghrelin pathways
- Tesamorelin 2mg AM + ipamorelin 200mcg 2× daily
- 18–20% (early observational studies, not peer-reviewed)
- Sustained multi-peak elevation throughout waking hours
- Off-label research use only
- Most mechanistically sound for maximizing daily GH exposure, but evidence base remains anecdotal—no published RCTs on the combination for VAT specifically